Drug
Spn 821
Spn 821: highest development phase Phase 2, developed by Supernus Pharmaceuticals. 1 trial record tracked on RxWires.
- Highest phase
- Phase 2
- Developer
- Supernus Pharmaceuticals
Trials
| Drug | Phase | Indication |
|---|---|---|
| SPN-821 2400 mg NCT07226661 | Phase 2 | Major Depressive Disorder (MDD) |
Latest
No recent events.
Follow Spn 821 on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.